Given the uniquely high intrinsic expression/function of GLUD1 in liver tumors, it is conceivable that targeting glutamate metabolism in HCC may provide a superior therapeutic window over strategies that attempt to inhibit mitochondrial metabolism at more ubiquitously expressed targets (e.g., complex I). The gene discussed is GLUD1; the disease is hepatocellular carcinoma.